Most pharma portfolio problems are not decision problems. They are evidence-timing problems. By the time a portfolio pack reaches leadership, the work has already moved: a risk was raised somewhere, an approval happened somewhere, a material delay was discussed somewhere. The decision record is incomplete exactly when the decision is being made.
Pharma portfolio governance is the practice of making those decisions on live, connected, traceable data instead of reconstructed snapshots. It connects the commercial view of molecules and portfolios with the execution view of projects, workstreams, tasks, risks, and issues.
The four questions governance has to answer
Every review - weekly, monthly, or at a phase gate - is really asking:
- What is moving? Which molecules and milestones advanced since last time.
- What is stuck? Blocked tasks, slipped dates, unresolved issues.
- Who owns it? Named accountability, not an email thread.
- What needs a decision? Go/no-go, re-baseline, escalate, or kill.
Why spreadsheets and generic tools run out
Spreadsheets and generic project tools track tasks and deadlines, but they do not understand pharma asset decisions - phase gates, go/kill scoring, PTRS, NPV/eNPV, patent fields, material readiness, or regulatory evidence. They also treat audit as an export or an afterthought, so readiness begins with searching folders instead of already existing.
What a governed operating model looks like
In practice, governance shows up as a connected hierarchy - portfolio, programme, molecule on the commercial side, and project, workstream, milestone, task, subtask on the execution side - where task-level progress rolls up into portfolio visibility, and leadership decisions flow back down into governed execution. Risk scoring, financial models, material readiness, and an append-only audit trail all attach to the same record, so a molecule call made today still holds up when someone asks “what changed?” years from now.